Chinese Herbal Medicine Treatment for Alzheimer's Disease Inpatients in China: Alternative or Complement to Conventional Medicine, a Cross-sectional Study
Chen, X.; Yan, H.; Nicholas, S.; Maitland, E.; Huang, Z.; Ma, Y.; Shi, X.
Show abstract
ObjectivesChinese herbal medicine (CHM), a typical type of complementary and alternative medicine (CAM), has been used to treat Alzheimers disease (AD) with costs covered by Chinas urban basic medical insurance. Previous studies have demonstrated the treatment effectiveness of CHM for intractable disease and CHMs ability to reduce medical costs. There has been no research exploring the impact of CHM on AD inpatient hospital costs or whether CHM is a complement or alternative to conventional medicine treatments. We compared the medical costs of AD inpatients, CHM users, and non-CHM users to analyze whether CHM has increased or decreased the AD inpatient costs, to assess whether CHM was an alternative or complementary treatment. MethodsOur cross-sectional research was based on a 5% random sample from the 2010 to 2016 Urban Employee Basic Medical Insurance (UEBMI) and Urban Resident Basic Medical Insurance (URBMI) claim data, yielding information on 1507 urban AD inpatients. Wilcoxon rank sum test and chi square test were applied to the medical cost data with an abnormal distribution. To control for confounding factors, such as demographic (age and sex) and medical costs, the influence between CHM costs and conventional medicine costs were analyzed by quantile regression. ResultsCHM users accounted for 79.83% (1203/1507) of the total inpatients. The median inpatient cost of CHM users was RMB13293.95 (USD2084.49), which was higher than non-CHM users (RMB8428.10/USD1321.53, P<0.001). The median CHM cost was RMB721.00 (USD113.05). Positive correlations between CHM users and CHM costs were found after controlling for confounder variables (Coef.=0.09, P<0.001). ConclusionDuring 2010-2016, nearly 80% of AD inpatients in our sample used CHM. Participation in CHM increased the total inpatient costs, pharmacy costs, and conventional medicine costs of AD inpatients over non-CHM users. CHM mainly plays a complementary or less alternative role to conventional medicine for AD treatment.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Socio-demographic characteristics and their relation to medical service consumption among elderly in Israel during the COVID-19 lockdown in 2020 compared to the corresponding period in 2019 93%
- Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: a population-based cohort study from Italy 93%
- Impact of the COVID-19 pandemic on cognitive function in Japanese community-dwelling older adults in a class for preventing cognitive decline 93%
Similar papers in this journal
- The Impact for implementing Balanced Scorecard in Health Care Organizations: A Systematic Review 92%
- A Systematic Review: The Dimensions and Indicators utilized in the Performance Evaluation of Health Care Organizations- An Implication during COVID-19 Pandemic 91%
- Differences in medication reconciliation interventions between six hospitals: a mixed method study 89%
Similar papers in this journal
- Comparison of Care Utilization and Medical Institutional Death among Older Adults by Home Care Facility Type: A Retrospective Cohort Study in Fukuoka, Japan 95%
- The impact of National Centralized Drug Procurement policy on the use of policy-related original and generic drugs in public medical institutions in China: A difference-in-difference analysis based on national database 94%
- International Prevalence Of Consultation With A Naturopathic Practitioner: A Systematic Review And Meta-Analysis 92%
Similar papers in this journal
- Metformin Is Associated with Favorable Outcomes in Patients with COVID-19 and Type 2 Diabetes Mellitus 93%
- Rapid Clinical Screening and Staging for COVID-19 Severe Outcome A Hospitalization Study in New York City 93%
- The use of angiotensin-converting enzyme inhibitors but not angiotensin receptor blockers in hospitalized patients with COVID-19 is associated with a lower risk of mortality 92%
Similar papers in this journal
- Construction and application of a revised satisfaction index model for Chinese urban and rural residents basic medical insurance 92%
- Development of a Mobile Application to Represent Food Intake in Inpatients: Dietary Data Systematization 90%
- Development of a data-driven COVID-19 prognostication tool to inform triage and step-down care for hospitalised patients in Hong Kong: A population based cohort study 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.